Skip to main content
Diabetes, Obesity, and Cardiometabolic CARE logoLink to Diabetes, Obesity, and Cardiometabolic CARE
. 2026 Jun 16;1(4):618–627. doi: 10.2337/doc25-0088

The Impact of Cognitive and Physical Impairments on Functional Limitations in Middle-Aged and Older Adults With Type 1 Diabetes

Pearl G Lee 1, Barbara H Braffett 2,✉, Naomi S Chaytor 3, Ionut Bebu 2, Catherine L Martin 1, Victoria R Trapani 2, José A Luchsinger 4, Gayle M Lorenzi 5, Rodica Pop-Busui 6, Rose A Gubitosi-Klug 7, Alan M Jacobson 8, William H Herman 9, Christopher M Ryan 10; DCCT/EDIC Research Group*
PMCID: PMC13644643  PMID: 42888976

Abstract

OBJECTIVE

Individuals with type 1 diabetes (T1D) are living longer and developing cognitive and physical impairments. The effect of these impairments on everyday functioning remains poorly understood. We evaluated whether cognitive and physical impairments were associated with functional status in participants from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.

RESEARCH DESIGN AND METHODS

Participants (n = 988) completed cognitive and physical function tests and self-reported ability to complete functional activities across five domains: activities of daily living (ADL), instrumental ADL (IADL), leisure and social activities, lower-extremity mobility, and general physical function.

RESULTS

Among the participants, 77% (mean age 60 years, diabetes duration 38 years) had neither cognitive nor physical impairments, 23% had either, and 7% had both. Depressive symptomology was reported by 12% and subjective cognitive decline by 22%. Participants with versus without both impairments were more likely to report functional limitations (87% vs. 39%, P < 0.001). Cognitive and/or physical impairments, depressive symptomatology, subjective cognitive decline, and neuropathy were associated with higher odds of functional limitations across all domains. Compared with men, women had higher odds of functional limitations, including any, IADL, leisure/social, lower-extremity mobility, and general physical. Higher hemoglobin A1c was associated with higher odds of ADL limitations. History of cardiovascular disease was marginally associated with mobility limitations.

CONCLUSIONS

Among middle-aged and older adults with T1D, functional limitations were common and associated with cognitive and physical impairments, depressive symptoms, subjective cognitive decline, and neuropathy. Identifying and addressing these factors may help preserve or improve functional status in aging adults with T1D.

Graphical Abstract

A poster summarises the impact of cognitive and physical impairments on functional limitations in middle aged and older adults with type 1 diabetes. Sections include objective, methods, participants, results, and key findings. Among 988 participants, 70 percent have no impairment, 9 percent have cognitive impairment only, 14 percent have physical impairment only, and 7 percent have both. Functional limitations are associated with older age, diabetes complications, depressive symptoms, self-reported cognitive decline, and higher glycated haemoglobin. Any functional limitation occurs in 48 percent of participants.

Introduction

Historically, individuals with type 1 diabetes (T1D) were reported to have reduced life expectancies. With improvements in care, many are living to older ages (1). In 2021, an estimated 1.7 million U.S. adults (5.7% of all adults with diagnosed diabetes) had T1D, including >33,000 aged >65 years (2). In older adults with T1D, clinical outcomes traditionally emphasized by providers, such as hyperglycemia and microvascular, neuropathic, and cardiovascular complications, are associated with both cognitive and physical impairments (3,4). However, the effects of these impairments on functional status, which is often of greatest importance to patients, have not been rigorously studied, particularly when cognitive and physical impairments co-occur —a condition commonly referred to as “cognitive frailty.” Functional independence has been consistently reported by older adults across multiple health care settings as an important health outcome to achieve. We evaluated the impact of cognitive and physical impairments, separately and in combination, on activities of daily living (ADL), instrumental activities of daily living (IADL), leisure and social activities, lower-extremity mobility, and general physical limitations in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort with T1D. We hypothesized that cognitive impairment, physical impairment, and their combination would affect functioning, with combined impairments having the greatest impact (Supplementary Fig. 1).

Research Design and Methods

DCCT/EDIC has been described previously (5–8). In brief, between 1983 and 1989, 1,441 individuals with T1D (median age 27 years; range 13–39 years) were enrolled in the DCCT and randomly assigned to intensive or conventional diabetes therapy (5). In 1993, after an average of 6.5 years of follow-up, the benefits of intensive glycemic therapy were demonstrated, the DCCT was stopped, and participants originally assigned to conventional therapy were taught intensive therapy. In 1994, 96% of the surviving cohort enrolled in the EDIC observational study, and all participants were returned to their health care providers for ongoing diabetes care (6). Hemoglobin A1c (HbA1c) levels in the intensive and conventional therapy groups converged early in EDIC and have remained at similar mean levels (7.2–8.0% [55–64 mmol/mol]) over time. In EDIC year 25 (2018), a mean of 32 years after DCCT randomization, all participants were invited to complete a battery of cognitive assessments and physical performance measures and to report their ability to complete daily activities.

Institutional review boards at all participating centers approved the study, and participants provided written informed consent. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Cognitive Impairment, Depressive Symptomatology, and Perception of Cognitive Decline

Cognition was assessed at DCCT baseline (1983–1989), DCCT years 2 (1985–1991) and 5 (1988–1993), and at EDIC years 12 (2005) and 25 (2018). The cognitive testing protocol, scoring, and quality control procedures have been described in detail (3,9). Three cognitive domains known to be more sensitive to the impact of glycemia were assessed: Immediate Memory, Delayed Recall, and Psychomotor and Mental Efficiency (10). For each test variable, a standardized z score was calculated using the means and SDs for the entire cohort at DCCT baseline, providing a unit-free measurement of the relative improvement (positive z score) or deterioration (negative z score) in performance compared with the total cohort at the DCCT baseline assessment. For each individual, the mean z score was calculated across each cognitive domain.

Cognitive impairment was assessed independently by three senior neuropsychologists masked to the participants’ treatment groups and biomedical data. They reviewed raw test scores and standardized z scores at each of the five assessments to determine current performance and change in performance over time (11,12). Sex, race, handedness, years of education, and Wechsler Verbal and Full-Scale IQ scores at study entry and Montreal Cognitive Assessment (MoCA) scores at EDIC year 25 were also available. Quantitative MoCA scores and review of raw MoCA answer sheets were considered in the overall determination of cognitive impairment status, given that published cutoff scores for possible mild cognitive impairment range from <26 to <18 (13).

To determine final cognitive ratings, the neuropsychologists met via videoconference to establish consensus. While strict algorithms were not used, specific guiding principles were followed. Normal profiles were those in which current test results fell within expectations given the participant’s demographic characteristics and baseline verbal IQ, without significant decline over 32 years. Instances where one or two current or prior assessment test scores fell below expectations were considered to be consistent with normal variability in cognitive performance. Impaired profiles were those in which current test performance was abnormal in multiple cognitive domains (>1.5–2 SD below the cohort baseline mean), and there was a decline in performance. Questionable participant profiles were those that were considered abnormal, but only met partial criteria for impairment and included 1) performance decline over time, but within normal limits, 2) lower than expected current performance without evidence of significant decline over time, 3) poor performance in only one domain, or 4) performance decline or low performance in multiple domains below the 1.5–2 SD threshold (11,12). Only 21 participants were classified as having impaired cognition, and 140 were classified as questionable impairment. These two groups were combined for this analysis and compared with the group with normal cognitive profiles.

Depressive symptomatology and subjective cognitive decline were assessed at EDIC year 25 using the Symptom Checklist-90 Revised (SCL-90R) (14) and the Cognitive Change Index (CCI) Self (15), respectively. The SCL-90R depression scale was used to assess the effects of mood on cognition, with T scores ≥63 indicating a possible depressive disorder (16). CCI scores range from 20 (better subjective cognition) to 100 (worse subjective cognition). We used a CCI cutoff of >35 to indicate subjective cognitive decline.

Physical Impairment

The Short Physical Performance Battery (SPPB) assessed balance, gait speed, and repeated chair stands and was used as an objective measure of lower-extremity mobility (2). The SPPB score, ranging from 0 (worst) to 12 (best score), was calculated as the sum of the scores for each SPPB component, with a SPPB score <10 indicating physical impairment (17). In older adults, SPPB scores <10 and reductions in scores over time have been shown to predict falls, disability, and mortality (17–19).

Functional Limitations

Self-reported functional limitations were assessed using items from the National Health and Nutrition Examination Survey (NHANES) questionnaire (20). Functional limitations were classified across five domains: ADL (such as bathing, dressing, and feeding), IADL (such as driving, shopping, and financial management), leisure and social activities, lower-extremity mobility, and general physical function (20–22). A domain-specific activity limitation was present if at least one item within the domain was answered “some difficulty,” “much difficulty,” or “unable to do” and was absent if all items in the domain were answered “no difficulty.” Responses of “do not do this activity,” “prefer not to answer,” and “don’t know” were treated as missing.

Glycemia and Diabetes-Related Complications

HbA1c was measured by high-performance liquid chromatography quarterly during DCCT and annually during EDIC (6). Severe hypoglycemia, defined as any event leading to coma and/or seizure within the 3-month time window before each DCCT/EDIC annual visit, was self-reported. Diabetes complications were assessed with standardized protocols throughout DCCT and EDIC (23–26). Proliferative diabetic retinopathy was defined by neovascularization or evidence of scatter photocoagulation observed on fundus photographs or by self-report. Clinically significant macular edema was defined by its presence on fundus photography, self-report, history, or evidence of focal photocoagulation or antivascular endothelial growth factor therapy. Kidney disease was defined as an albumin excretion rate ≥30 mg/24 h or urine albumin-to-creatinine ratio ≥30 mg/g on two or more consecutive visits or an estimated glomerular filtration rate <60 mL/min/1.73 m2. Diabetic peripheral neuropathy was defined by a Michigan Neuropathy Screening Instrument (MNSI) questionnaire score ≥4 and an MNSI examination score ≥2.5 (27). Cardiovascular disease (CVD) was defined as nonfatal stroke, nonfatal myocardial infarction, “silent” myocardial infarction identified using centrally evaluated electrocardiograms, angina, coronary revascularization, or congestive heart failure as reported by participants and confirmed by medical records. All CVD events were adjudicated. Cardiovascular autonomic neuropathy was defined as an R–R variation <15, R–R variation 15–19, and Valsalva ratio of ≤1.5, or a postural drop in diastolic blood pressure ≥10 mmHg on standardized cardiovascular testing.

Statistical Analyses

Quantitative covariates (e.g., HbA1c) were characterized by the time-weighted mean of all DCCT/EDIC follow-up values from DCCT baseline to EDIC year 25 (2018), weighting each value by the time interval since the last measurement. Categorical covariates were defined as any report between DCCT baseline and EDIC year 25.

The cognitive rating (normal vs. questionable/impaired) and the physical function measurement (SPPB ≥10 vs. <10) were combined to create a four-level cognitive and physical impairment variable (no cognitive or physical impairment, cognitive impairment only, physical impairment only, or both cognitive and physical impairment). The analyses include 988 participants with both cognitive ratings and SPPB measurements. The Wilcoxon rank sum test was used to assess group differences in quantitative measurements, and the χ2 test was used to assess group differences in categorical measurements. Separate logistic regression models were used to evaluate the associations of sociodemographic characteristics, risk factors, diabetes-related complications, self-reported symptoms, and cognitive and physical impairments with each activity limitation, adjusting for age and sex. Comprehensive multivariable regression models were then developed for each activity limitation outcome using backward elimination, where variables significant at P < 0.10 were retained at each step. The final multivariable models retained covariates significant at P < 0.05. Signed z values are presented and correspond to the magnitude and directionality of the association with a |z| ≥3.89 equivalent to P < 0.0001 (two-sided). A group-by-sex interaction was evaluated in each final multivariable model. Results nominally significant at P < 0.05 (two-sided) are reported. All analyses were performed using SAS 9.4 and R statistical software.

Data and Resource Availability

Data collected for the DCCT/EDIC study through 30 June 2022 are available to the public through the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository (https://repository.niddk.nih.gov/studies/edic/). Data collected in the current cycle (July 2022–June 2027) will be available to the public within 2 years after the end of the funding cycle.

Results

The characteristics of the DCCT/EDIC participants, stratified by cognitive and/or physical impairment, are summarized in Table 1. The 988 participants were a median age of 60 years, and the median diabetes duration was 38 years. Compared with those included, participants not included were older but did not differ with respect to sex, education, BMI, HbA1c, or diabetes duration (data not shown).

Table 1.

Participant characteristics and diabetes-related complications by cognitive and/or physical impairment status

  Overall (N = 988) Neither cognitive nor physical (n = 686) Cognitive or physical or both (n = 302) P value
Sociodemographic        
 Age (years) 60 (55, 65) 59 (54, 64) 62 (58, 67) <0.0001
 Female sex 470 (48) 332 (48) 138 (46) 0.4335
 Non-Hispanic White race* 950 (96) 661 (96) 289 (96) 0.6190
 Education (years) 16 ± 2 16 ± 2 15 ± 2 <0.0001
 Professional or technical occupation 539 (55) 403 (59) 136 (45) <0.0001
 Current cigarette smoker 68 (7) 40 (6) 28 (9) 0.0491
 Current occasional or regular alcohol use 504 (51) 363 (53) 141 (47) 0.0679
Physical examination        
 BMI (kg/m2) 29.3 ± 5.9 28.9 ± 5.5 30.2 ± 6.5 0.0112
 Blood pressure (mmHg)        
  Systolic 125 ± 15 124 ± 14 127 ± 16 0.0055
  Diastolic 69 ± 9 69 ± 9 69 ± 9 0.8282
Laboratory values        
 HbA1c (%) 7.7 ± 1.1 7.7 ± 1.1 7.9 ± 1.2 0.0012
 HbA1c (mmol/mol) 61 ± 12 60 ± 12 63 ± 13 0.0012
 Plasma lipids (mmol/L)        
  Total cholesterol 4.4 ± 1.0 4.3 ± 0.9 4.5 ± 1.0 0.0430
  HDL cholesterol 1.7 ± 0.5 1.7 ± 0.5 1.6 ± 0.6 0.0286
  LDL cholesterol 2.3 ± 0.8 2.3 ± 0.8 2.4 ± 0.8 0.0328
  Triglycerides 0.8 ± 0.6 0.8 ± 0.5 1.0 ± 0.7 <0.0001
Diabetes history and complications†        
 Duration of diabetes (years) 38 (34, 42) 38 (34, 42) 39 (35, 43) 0.0009
 Proliferative diabetic retinopathy 270 (27) 164 (24) 106 (35) 0.0003
 Clinically significant macular edema 299 (30) 186 (27) 113 (37) 0.0012
 Sustained AER ≥30 mg/24 h 305 (31) 184 (27) 121 (40) <0.0001
 eGFR <60 mL/min/1.73 m2 124 (13) 62 (9) 62 (21) <0.0001
 Diabetic peripheral neuropathy 341 (36) 195 (29) 146 (52) <0.0001
 Cardiovascular disease 115 (12) 64 (9) 51 (17) 0.0007
 Cardiovascular autonomic neuropathy 418 (42) 248 (36) 170 (56) <0.0001

Data are presented as means ± SD, n (%), or median (interquartile range) unless otherwise indicated. AER, albumin excretion rate; eGFR, estimated glomerular filtration rate.

*Race was self-assigned.

†Any report between DCCT baseline and EDIC year 25.

Participants with cognitive and/or physical impairments were significantly older, had less education, and were less likely to have professional or technical occupations than participants without impairments (Table 1). Participants with cognitive and/or physical impairments also had higher BMIs, systolic blood pressures, and HbA1c levels, and unfavorable lipid profiles compared with participants with neither impairment. A significantly higher proportion of participants with cognitive and/or physical impairments had histories of retinopathy, kidney disease, peripheral neuropathy, CVD, and cardiovascular autonomic neuropathy compared with those without impairments.

Cognitive and physical impairment ratings, self-reported symptoms, and activity limitations are presented in Table 2. Among the participants, 161 (16%) met criteria for questionable or impaired cognition, and 209 (21%) had some physical impairment. A total of 686 participants (70%) had neither cognitive nor physical impairments, 234 (23%) had either cognitive or physical impairments, and 68 (7%) had both. There were 118 participants (12%) who reported depressive symptomatology (16% in men vs. 7% in women, P < 0.0001), and 218 (22%) reported subjective cognitive decline. Subjective cognitive decline was associated with objective cognitive impairment. Among participants with adjudicated cognitive impairment, 37.6% reported subjective cognitive decline, compared with 19.4% among those without objective impairment. The majority of participants who reported subjective cognitive decline did not meet the criteria for adjudicated cognitive impairment (72.9%). A total of 472 participants (48%) reported one or more functional limitations.

Table 2.

Cognitive, physical, and functional outcomes by cognitive and/or physical impairment status

  Definition/threshold Overall (N = 988) Neither cognitive nor physical (n = 686) Cognitive or physical or both (n = 302) P value
Cognitive consensus rating          
 Normal Current performance within expectations 827 (84) 686 (100) 141 (47) <0.0001
 Questionable Abnormal but only partial criteria for impairment met 140 (14) — 140 (46)  
 Impaired Abnormal in multiple domains 21 (2) — 21 (7)  
SPPB score          
 ≥10   779 (79) 686 (100) 93 (31) <0.0001
 <10 Physical impairment threshold 209 (21) — 209 (69)  
Combined cognitive/physical impairment*          
 No cognitive or physical impairment Normal cognition and SPPB ≥10 686 (69) 686 (100) — <0.0001
 Cognitive impairment only Questionable/impaired cognition; SPPB ≥10 93 (9) — 93 (31)  
 Physical impairment only Normal cognition; SPPB <10 141 (14) — 141 (47)  
 Both cognitive and physical impairment Questionable/impaired cognition; SPPB <10 68 (7) — 68 (23)  
Self-reported symptoms          
 SCL-90R Depression T score ≥63 Threshold indicating possible depressive disorder 118 (12) 62 (9) 56 (19) <0.0001
 CCI >35 Subjective cognitive decline (higher = worse) 218 (22) 124 (18) 94 (32) <0.0001
Self-reported activity limitations†          
 Any activity limitation ≥1 item in any domain 472 (48) 268 (39) 204 (68) <0.0001
 ADL limitation e.g., bathing, dressing, feeding 158 (16) 68 (10) 90 (30) <0.0001
 IADL limitation e.g., driving, shopping, financial management 165 (17) 72 (11) 93 (31) <0.0001
 Leisure and social activity limitation   128 (13) 46 (7) 82 (27) <0.0001
 Lower-extremity mobility limitation   189 (19) 78 (11) 111 (37) <0.0001
 General physical limitation   458 (47) 259 (38) 199 (66) <0.0001

Data are n (%) unless otherwise indicated.

*Defined by a cognitive consensus rating (questionable/impaired vs. normal) in combination with SPPB score (<10 vs. ≥10).

†Assessed using items from the NHANES questionnaire. Domain-specific limitation present if ≥1 item answered “some difficulty,” “much difficulty,” or “unable to do.”

Functional limitations varied by cognitive and physical impairment status: 58% of participants with cognitive impairment only, 66% with physical impairment only, and 87% with both cognitive and physical impairments reported one or more functional limitations compared with 39% of participants with no cognitive or physical impairments (Fig. 1). A significantly higher proportion of participants with both cognitive and physical impairments reported functional limitations in each functional domain compared with those with neither cognitive nor physical impairments (P < 0.001 for each). For example, 87% of participants with both cognitive and physical impairments reported general physical limitations versus 38% of participants with neither cognitive nor physical impairments. Participants with physical impairment only were more likely to report ADL limitations and lower-extremity mobility limitations compared with participants with cognitive impairment only.

Figure 1.

A set of bar charts compares functional limitations across impairment groups labelled neither, cognitive only, physical only, and both. Categories include any activity, activities of daily living, instrumental activities of daily living, leisure and social activity, lower extremity mobility, and general physical activity. Percentages increase across most categories from neither to both impairments. The both impairment group shows the highest values, including 87 percent for any activity and general physical activity, and 61 percent for lower extremity mobility.

Prevalence of activity limitations as a function of cognitive or physical impairments and both impairments, unadjusted. The combined four-level cognitive and physical impairment variable was defined by a cognitive consensus rating (normal vs. questionable/impaired) in combination with an SPPB <10. The overall P value was <0.001 for each of the six comparisons (yes/no activity limitation vs. four-level cognitive/physical impairment). For each bar graph, pairwise comparisons were also evaluated. *Significantly different from “Neither.” †Significantly different from “Both.” §For ADL and lower-extremity mobility, the “Cognitive only” group was significantly different from the “Physical only” group.

The associations between sociodemographic characteristics, cardiometabolic risk factors, diabetes-related complications, self-reported symptoms, and cognitive and physical impairments and functional limitations overall and within the five functional domains, adjusted for age and sex, are presented in Supplementary Table 1. Fewer years of education, higher BMI, pulse rate, and HbA1c, lower HDL cholesterol, and a history of severe hypoglycemia, retinopathy, kidney disease, CVD, and peripheral and cardiovascular autonomic neuropathy were each associated with higher odds of any activity limitation. Limitations in all five of the functional domains were significantly associated with similar sets of risk factors. Depressive symptomology and/or subjective cognitive decline were associated with higher odds of any limitations across all activity domains.

Covariates associated with functional limitations and their various domains are presented in Table 3. For each model, covariates are listed in order of the unsigned covariate z value (or P value) to designate their relative importance in the models. Older age was the most important risk factor for any activity limitation (odds ratio [OR] 1.88 per 5 years; 95% CI 1.65–2.14; P < 0.001), followed by history of cardiovascular autonomic neuropathy (OR 2.34; 95% CI 2.02–2.66; P < 0.001). Other important risk factors, in decreasing order of significance, included female versus male sex, peripheral neuropathy, depressive symptomology, subjective cognitive decline, any physical impairment, lower HDL cholesterol, and both cognitive and physical impairment. Across most functional domains, the presence of a physical impairment, combined cognitive and physical impairment, depressive symptomology, subjective cognitive decline, history of cardiovascular autonomic neuropathy, and peripheral neuropathy were associated with higher odds of functional limitations. Higher HbA1c was associated with higher odds of ADL limitations (OR 1.36 per 10 mmol/mol; 95% CI 1.09–1.68; P = 0.006). Compared with men, women had higher odds of any limitation (OR 2.37), IADL limitation (OR 1.57), leisure and social limitation (OR 1.73), lower-extremity mobility limitation (OR 1.84), and general physical limitation (OR 1.68). A history of CVD was marginally associated with higher odds of lower-extremity mobility limitations (OR 1.81; P = 0.030).

Table 3.

Associations of sociodemographic characteristics, cardiometabolic risk factors, diabetes-related complications, self-reported symptoms, and cognitive and physical impairments with activity limitations

  OR 95% CI z value P value
Any activity          
 Age (per 5 years) 1.88 1.65 2.14 9.54 <0.001
 Cardiovascular autonomic neuropathy (yes vs. no)* 2.34 2.02 2.66 5.24 <0.001
 Sex (female vs. male) 2.37 2.01 2.74 4.62 <0.001
 Diabetic peripheral neuropathy (yes vs. no)* 2.17 1.83 2.50 4.50 <0.001
 SCL-90R Depression T score ≥63 (yes vs. no) 3.80 3.21 4.39 4.40 <0.001
 CCI >35 (yes vs. no) 2.25 1.82 2.67 3.74 <0.001
 Physical impairment only (yes vs. no)† 2.14 1.67 2.61 3.18 0.002
 HDL cholesterol (per 0.1 mmol/L)‡ 0.92 0.88 0.97 −3.13 0.002
 Cognitive and physical impairment (both vs. neither)† 3.69 2.81 4.58 2.90 0.004
ADL        
 CCI >35 (yes vs. no) 2.67 2.22 3.13 4.24 <0.001
 Physical impairment only (yes vs. no)† 2.90 2.39 3.40 4.14 <0.001
 Cognitive and physical impairment (both vs. neither)† 3.34 2.69 3.99 3.63 <0.001
 Cardiovascular autonomic neuropathy (yes vs. no)* 2.01 1.59 2.43 3.28 0.001
 Diabetic peripheral neuropathy (yes vs. no)* 1.91 1.47 2.35 2.88 0.004
 SCL-90R Depression T score ≥63 (yes vs. no) 2.13 1.59 2.66 2.77 0.006
 HbA1c (per 10 mmol/mol)‡ 1.36 1.09 1.68 2.75 0.006
IADL        
 Physical impairment only (yes vs. no)† 3.13 2.64 3.62 4.55 <0.001
 SCL-90R Depression T-score ≥63 (yes vs. no) 3.20 2.68 3.73 4.35 <0.001
 Diabetic peripheral neuropathy (yes vs. no)* 2.28 1.87 2.69 3.97 <0.001
 CCI >35 (yes vs. no) 2.32 1.88 2.77 3.73 <0.001
 Cardiovascular autonomic neuropathy (yes vs. no)* 1.71 1.31 2.11 2.63 0.009
 Sex (female vs. male) 1.57 1.16 1.97 2.19 0.028
 Education (per 1 year) 0.89 0.79 1.00 −2.13 0.033
Leisure and social activity        
 Cognitive and physical impairment (both vs. neither)† 5.20 4.54 5.87 4.85 <0.001
 Diabetic peripheral neuropathy (yes vs. no)* 3.02 2.57 3.47 4.79 <0.001
 Physical impairment only (yes vs. no)† 3.16 2.61 3.71 4.09 <0.001
 Cognitive impairment only (yes vs. no)† 3.24 2.61 3.86 3.68 <0.001
 SCL-90R Depression T score ≥63 (yes vs. no) 2.70 2.13 3.27 3.42 <0.001
 CCI >35 (yes vs. no) 2.24 1.75 2.73 3.24 0.001
 Sex (female vs. male) 1.73 1.28 2.17 2.40 0.017
Lower-extremity mobility        
 Physical impairment only (yes vs. no)† 3.41 2.94 3.88 5.07 <0.001
 Cognitive and physical impairment (both vs. neither)† 5.23 4.56 5.89 4.88 <0.001
 Diabetic peripheral neuropathy (yes vs. no)* 2.39 2.00 2.78 4.38 <0.001
 BMI (per 1 kg/m2)‡ 1.10 1.06 1.15 4.36 <0.001
 CCI >35 (yes vs. no) 2.23 1.79 2.67 3.56 <0.001
 Sex (female vs. male) 1.84 1.45 2.24 3.04 0.002
 Age (per 5 years) 1.23 0.07 1.42 2.81 0.005
 CVD (yes vs. no)* 1.81 1.28 2.35 2.16 0.030
General physical        
 Age (per 5 years) 1.87 1.64 2.13 9.27 <0.001
 Cardiovascular autonomic neuropathy (yes vs. no)* 2.09 1.77 2.42 4.50 <0.001
 Diabetic peripheral neuropathy (yes vs. no)* 2.00 1.66 2.34 4.00 <0.001
 SCL-90R Depression T score ≥63 (yes vs. no) 3.14 2.56 3.71 3.89 <0.001
 CCI >35 (yes vs. no) 2.24 1.82 2.66 3.78 <0.001
 Cognitive and physical impairment (both vs. neither)† 4.08 3.18 4.97 3.08 0.002
 Physical impairment only (yes vs. no)† 1.94 1.47 2.41 2.75 0.006
 Diastolic blood pressure (per 5 mmHg)‡ 0.79 0.65 0.95 −2.55 0.011
 Sex (female vs. male) 1.68 1.28 2.08 2.53 0.012
 Pulse rate (per 1 bpm)‡ 1.03 1.00 1.06 2.25 0.025
 HDL cholesterol (per 0.1 mmol/L)‡ 0.94 0.89 0.99 −2.25 0.025
 BMI (per 1 kg/m2)‡ 1.04 1.00 1.09 1.98 0.047

ORs (95% CIs) and P values from six separate multivariable logistic regression models evaluating the association of each covariate of interest (independent) with each activity limitation. Covariates are listed in order of significance as indicated by the absolute z value. There were no significant group-by-sex interactions across all six models.

*Any report between DCCT baseline and the EDIC year 25 study visit.

†Defined by a cognitive consensus rating (questionable/impaired vs. normal) in combination with an SPPB <10.

‡Risk factors (e.g., HbA1c) were characterized by the time-weighted mean values of all follow-up values since DCCT baseline up to the EDIC year 25 study visit.

Conclusions

In this study of middle-aged and older adults with T1D, we examined the impact of cognitive and physical impairments, separately and in combination, on self-reported functional limitations. Individuals with both cognitive and physical impairments were most likely to report functional limitations compared with those without cognitive or physical impairments.

Previously, we compared the prevalence of self-reported functional limitations among DCCT/EDIC participants (median age of 60 years) with published estimates for U.S. adults aged ≥65 years (4). Among the DCCT/EDIC participants, 48% reported functional limitations, within the range of 50–77% reported for U.S. adults, ∼20% of whom have type 2 diabetes (4). The somewhat lower prevalence in our cohort likely reflects the younger age and overall better health of individuals selected for the DCCT. Sex-stratified comparisons further contextualize these findings: prevalence among DCCT/EDIC women (50%) and men (46%) closely resembled rates in non-Hispanic White adults without diabetes (women: 54.2%, mean age 64.6 years; men: 42.1%, mean age 63.0 years), yet were substantially lower than rates in non-Hispanic White adults with diabetes (women: 79.3%, mean age 67.0 years; men: 66.9%, mean age 66.0 years) (28). When considering specific functional domains, ADL and IADL limitation rates in our sample (ADLs: 16%; IADLs: 17%) were comparable to those of same-aged adults in the general population (ages 50–64 years, ADLs: 15%; IADLs: 17%), but notably lower than rates among adults with diabetes (ADLs: 28%; IADLs: 30%) (29). Collectively, these findings suggest that functional limitation rates in T1D are broadly similar to those of the general population and meaningfully lower than those observed in adults with type 2 diabetes.

The DCCT/EDIC cohort performed relatively well on both the cognitive and physical function assessments: 84% had no significant cognitive impairment, and 79% had no significant physical impairment. However, a sizeable minority (30%) had cognitive or physical impairments or both. Given that 48% of the cohort reported some limitation in functional activities, factors other than cognitive and physical impairments impact individuals’ abilities to perform these activities. We found that limitations in ADLs, IADLs, leisure and social activities, and general physical activities were all associated with depressive symptomatology, consistent with literature reporting these associations in the general population (28,29). Likewise, subjective cognitive decline was associated with limitations in all functional domains. This might reflect subclinical cognitive changes that are not yet detectable by cognitive assessments but are interfering with functional activities (30). We also found that neuropathy was a significant risk factor for limitations in physical activities across all categories, consistent with the literature (31). Interestingly, history of retinopathy requiring treatment and CVD were not significant risk factors for functional limitations. Advances in treatments that maintain visual and cardiovascular function may account for this finding.

While individuals with physical impairments only were more likely than those with cognitive impairments only to report limitations in all activity domains, the difference was only significant for limitations in ADLs and lower-extremity mobility. This finding is expected since ADLs and lower-extremity mobility depend more on physical functioning. Individuals with cognitive impairment only were as likely to have limitations in IADLs, leisure and social activities, and general physical activities as those with physical impairments only (32). While this finding was somewhat unexpected since IADLs and leisure and social activities are generally more reliant on higher cognitive functioning, most IADLs also have physical requirements that may limit activity despite intact cognition. Interestingly, women had higher odds of any functional limitations, IADL limitations, leisure and social limitations, lower-extremity mobility limitations, and general physical limitations. Our findings suggest that in middle-aged and older adults with T1D, cognitive and physical functioning are both important to IADLs, leisure and social activities, and general physical activities. A meta-analysis of the associations between cognitive functioning and ADLs in healthy adults, adults with mild cognitive impairment, and adults with dementia revealed that performance of ADLs and IADLs was associated with global cognition, while IADLs were also associated with executive functioning and visual-spatial skills (33). Further, consistent with our findings of 7% with combined cognitive and physical impairment, a 2023 review found a prevalence of 1.4% to 39.3% in community-dwelling older adults, which was associated with a higher odds of ADL and IADL limitations (34).

The strengths of our study are a large, well-characterized population of adults with T1D and the long-term, rigorously collected information about risk factors, complications and comorbidities, and cognitive and physical function. Cognitive impairment was determined by consensus among three masked senior neuropsychologists using longitudinal assessments of immediate memory, delayed recall, psychomotor and mental efficiency, and global mental status.

Limitations are that the study cohort is likely not representative of the general population with T1D. In addition, only 2.4% of participants met the full criteria for cognitive impairment. This study was cross-sectional, so the direction of the associations cannot be determined. Finally, self-report of functional limitations may be biased in those with greater cognitive impairment (e.g., lack of insight), and/or with depressive symptomology (e.g., negative self-appraisal) (35–37). The multivariable models reported herein were developed using backward selection. While this approach has the advantage of evaluating joint associations among all variables initially included in the model and then sequentially removing the least influential predictors, it may also result in the early exclusion of variables that could become relevant at later stages of the modeling process.

Our findings underscore the importance of comprehensive geriatric assessment in middle-aged and older adults with long-standing T1D. Cognitive and physical impairments, depressive symptoms, subjective cognitive decline, and neuropathy were strongly associated with functional limitations across multiple domains, including activities of daily living, mobility, and social engagement. Routine screening for these risk factors—particularly combined cognitive and physical impairment—may help clinicians identify individuals at greatest risk for loss of independence. Integrating cognitive and physical performance evaluations into diabetes care, alongside interventions and patient education targeting the impact of depression and neuropathy on independence in late life, could support functional preservation and improve quality of life as this population ages. The current American Diabetes Association “Standards of Care in Diabetes” recognizes that functional ability is central to diabetes management in older adults with diabetes and recommends annual assessments for geriatric syndromes (e.g., cognitive impairment, frailty, falls, depression, mobility limitations), as well as assessment of self-management abilities, to guide individualized care and planning. Our findings support the implementation of the 4Ms framework developed by the Age-Friendly Health Systems initiatives—Matters, Mobility, Mentation, and Medication— where patient priorities such as functional independence (Matters) are the focus of the care plan, and physical ability (Mobility), cognition/depression (Mentation), and Medications are regularly assessed as part of the clinical care (38). Easily implemented and validated screening tests are available for use in primary care and other medical settings (e.g., MoCA, Patient Health Questionnaire-9 depression screening).

In summary, among middle-aged and older adults with T1D, cognitive and physical impairments, depressive symptoms, subjective cognitive decline, female sex, older age, and neuropathy were associated with limitations in ADL, IADL, lower-extremity mobility, leisure and social activities, and general physical activities. In clinical care, cognitive and physical performance assessments and assessments for depression, subjective cognitive decline, and neuropathy may help to identify risk for functional limitations and guide clinical care for older individuals with long-duration T1D. Future research should evaluate the longitudinal relationships between the risk factors identified here and subsequent loss of functional independence, as well as the potential benefits of remediating these factors.

This article contains supplementary material online at https://doi.org/10.2337/figshare.32233443.

Acknowledgments

Article Information

Acknowledgments

The DCCT/EDIC Research Group owes its scientific success and public health contributions to the dedication and commitment of the DCCT/EDIC participants.

The sponsor of this study is represented by the National Institute of Diabetes and Digestive and Kidney Diseases Project Scientist, who serves as part of the DCCT/EDIC Research Group and plays a part in the study design and conduct, as well as the review and approval of manuscripts. The National Institute of Diabetes and Digestive and Kidney Diseases Project Scientist was not a member of the writing group of this article. The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies.

Industry contributors have had no role in the DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants’ adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton, Dickinson and Company (Franklin Lakes, NJ), Eli Lilly (Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA), Lifescan (Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Ft. Lauderdale, FL), Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche Diabetes Care (Indianapolis, IN), and Sanofi (Bridgewater, NJ).

Duality of Interest

No potential conflicts of interest relevant to this article were reported.

Author Contributions

All listed authors contributed significantly to the work. P.G.L., B.H.B., W.H.H., and C.M.R. contributed to the study concept and design and wrote the first draft of the manuscript. B.H.B., I.B., and V.R.T. conducted the statistical analyses. The remaining authors wrote sections of the manuscript and reviewed and edited the manuscript. All authors approved the final version of the manuscript. B.H.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding Statement

This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (grants U01 DK094176 and U01 DK094157), and through previous support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present), Bethesda, MD. J.A.L was supported by National Institute on Aging grant K24AG045334.

Footnotes

*A complete list of members in the DCCT/EDIC Research Group is presented in the supplementary material online.

Supporting information

Supplementary Material
docm250088_supp.zip (470.8KB, zip)

References

  • 1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group . Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care 2016;39:1378–1383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Fang M, Wang D, Selvin E. Prevalence of type 1 diabetes among US children and adults by age, sex, race, and ethnicity. JAMA 2024;331:1411–1413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Jacobson AM, Ryan CM, Braffett BH, et al.; DCCT/EDIC Research Group . Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes Endocrinol 2021;9:436–445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Martin CL, Trapani VR, Backlund J-YC, et al.; DCCT/EDIC Research Group . Physical function in middle-aged and older adults with type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2022;45:2037–2045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. The DCCT Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 [DOI] [PubMed] [Google Scholar]
  • 6. The Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group . Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Nathan DM, DCCT/EDIC Research Group . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9–16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Nathan DM, Bayless M, Cleary P, et al.; DCCT/EDIC Research Group . Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013;62:3976–3986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Jacobson AM, Musen G, Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group . Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842–1852 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Strauss ES, Sherman EMS, Spreen OA. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, Oxford University Press, 2006 [Google Scholar]
  • 11. Chaytor NS, Trapani VR, Braffett BH, et al. Utility of the NIH Toolbox Cognition Battery in middle to older aged adults with longstanding type 1 diabetes: the DCCT/EDIC study. Clin Neuropsychol 2024;38:1007–1027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Karger AB, Nasrallah IM, Braffett BH, et al.; DCCT/EDIC Research Group . Plasma biomarkers of brain injury and their association with brain MRI and cognition in type 1 diabetes. Diabetes Care 2024;47:1530–1538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699 [DOI] [PubMed] [Google Scholar]
  • 14. The DCCT Research Group . Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996;19:195–203 [DOI] [PubMed] [Google Scholar]
  • 15. Rattanabannakit C, Risacher SL, Gao S, et al. The Cognitive Change Index as a measure of self and informant perception of cognitive decline: relation to neuropsychological tests. J Alzheimers Dis 2016;51:1145–1155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Derogatis LR. SCL-90: Administration, Scoring & Procedures Manual for the R (evised) Version and Other Instruments of the Psychopathology Rating Scale Series. S.N, 1977 [Google Scholar]
  • 17. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556–561 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Vasunilashorn S, Coppin AK, Patel KV, et al. Use of the Short Physical Performance Battery Score to predict loss of ability to walk 400 meters: analysis from the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2009;64:223–229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–M94 [DOI] [PubMed] [Google Scholar]
  • 20. Centers for Disease Control and Prevention. National Health and Nutrition Survey 2013–2014 questionnaire variable list . Accessed 30 May 2024. Available from https://wwwn.cdc.gov/nchs/nhanes/search/variablelist.aspx?Cycle=2013-2014
  • 21. Jindai K, Nielson CM, Vorderstrasse BA, Quiñones AR. Multimorbidity and functional limitations among adults 65 or older, NHANES 2005–2012. Prev Chronic Dis 2016;13:E151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care 2010;33:1055–1060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Braffett BH, Gubitosi-Klug RA, Albers JW, et al.; DCCT/EDIC Research Group . Risk Factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2020;69:1000–1010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group . Risk factors for cardiovascular disease in type 1 diabetes. iabetes 2016;65:1370–1379 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Hainsworth DP, Bebu I, Aiello LP, et al.; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group . Risk factors for retinopathy in type 1 diabetes: the DCCT/EDIC Study. Diabetes Care 2019;42:875–882 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Perkins BA, Bebu I, de Boer IH, et al.; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group . Risk factors for kidney disease in type 1 diabetes. Diabetes Care 2019;42:883–890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Herman WH, Pop-Busui R, Braffett BH, et al.; DCCT/EDIC Research Group . Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med 2012;29:937–944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Albanese AM, Bartz-Overman C, Parikh Md T, Thielke SM. Associations between activities of daily living independence and mental health status among Medicare managed care patients. J Am Geriatr Soc 2020;68:1301–1306 [DOI] [PubMed] [Google Scholar]
  • 29. Bowling CB, Deng L, Sakhuja S, Morey MC, Jaeger BC, Muntner P. Prevalence of activity limitations and association with multimorbidity among US adults 50 to 64 years old. J Gen Intern Med 2019;34:2390–2396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. You M, Lindbergh CA, La Joie R, et al. Predicting brain atrophy and cognitive aging trajectories with baseline subjective cognitive concerns in cognitively normal older adults. Neurobiol Aging 2024;143:1–9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Brown SJ, Handsaker JC, Bowling FL, Boulton AJM, Reeves ND. Diabetic peripheral neuropathy compromises balance during daily activities. Diabetes Care 2015;38:1116–1122 [DOI] [PubMed] [Google Scholar]
  • 32. Bruderer-Hofstetter M, Gorus E, Cornelis E, Meichtry A, De Vriendt P. Influencing factors on instrumental activities of daily living functioning in people with mild cognitive disorder—a secondary investigation of cross-sectional data. BMC Geriatr 2022;22:791–798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Raimo S, Maggi G, Ilardi CR, et al. The relation between cognitive functioning and activities of daily living in normal aging, mild cognitive impairment, and dementia: a meta-analysis. Neurol Sci 2024;45:2427–2443 [DOI] [PubMed] [Google Scholar]
  • 34. Tang KF, Teh P-L, Lee SWH. Cognitive frailty and functional disability among community-dwelling older adults: a systematic review. Innov Aging 2023;7:igad005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Steward KA, Bull TP, Kennedy R, Crowe M, Wadley VG. Neuropsychological correlates of anosognosia for objective functional difficulties in older adults on the mild cognitive impairment spectrum. Arch Clin Neuropsychol 2020;35: 365–376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Steward KA, Kennedy R, Erus G, Nasrallah IM, Wadley VG. Poor awareness of IADL deficits is associated with reduced regional brain volume in older adults with cognitive impairment. Neuropsychologia 2019;129:372–378 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Numbers K, Jang S, Brodaty H, Sachdev PS, Draper B, Reppermund S. Instrumental activities of daily living by subjective and objective measures: the impact of depression and personality. Front Aging Neurosci 2022;14:829544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. The John A. Hartford Foundation . Age-Friendly Health Systems Initiative. Accessed 18 December 2025. Available from https://www.johnahartford.org/grants-strategy/current-strategies/age-friendly/age-friendly-health-systems-initiative

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material
docm250088_supp.zip (470.8KB, zip)

Articles from Diabetes, Obesity, and Cardiometabolic CARE are provided here courtesy of American Diabetes Association

RESOURCES